189 related articles for article (PubMed ID: 27354683)
1. Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon α kinoid phase I/II study.
Ducreux J; Houssiau FA; Vandepapelière P; Jorgensen C; Lazaro E; Spertini F; Colaone F; Roucairol C; Laborie M; Croughs T; Grouard-Vogel G; Lauwerys BR
Rheumatology (Oxford); 2016 Oct; 55(10):1901-5. PubMed ID: 27354683
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid.
Lauwerys BR; Hachulla E; Spertini F; Lazaro E; Jorgensen C; Mariette X; Haelterman E; Grouard-Vogel G; Fanget B; Dhellin O; Vandepapelière P; Houssiau FA
Arthritis Rheum; 2013 Feb; 65(2):447-56. PubMed ID: 23203821
[TBL] [Abstract][Full Text] [Related]
3. Active immunisation of human interferon α transgenic mice with a human interferon α Kinoid induces antibodies that neutralise interferon α in sera from patients with systemic lupus erythematosus.
Mathian A; Amoura Z; Adam E; Colaone F; Hoekman MF; Dhellin O; Vandepapelière P; Haroche J; Piette JC; Lebon P; Grouard-Vogel G
Ann Rheum Dis; 2011 Jun; 70(6):1138-43. PubMed ID: 21389044
[TBL] [Abstract][Full Text] [Related]
4. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus.
Yao Y; Richman L; Higgs BW; Morehouse CA; de los Reyes M; Brohawn P; Zhang J; White B; Coyle AJ; Kiener PA; Jallal B
Arthritis Rheum; 2009 Jun; 60(6):1785-96. PubMed ID: 19479852
[TBL] [Abstract][Full Text] [Related]
5. IFN-α kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study.
Houssiau FA; Thanou A; Mazur M; Ramiterre E; Gomez Mora DA; Misterska-Skora M; Perich-Campos RA; Smakotina SA; Cerpa Cruz S; Louzir B; Croughs T; Tee ML
Ann Rheum Dis; 2020 Mar; 79(3):347-355. PubMed ID: 31871140
[TBL] [Abstract][Full Text] [Related]
6. Anti-interferon alpha treatment in SLE.
Kirou KA; Gkrouzman E
Clin Immunol; 2013 Sep; 148(3):303-12. PubMed ID: 23566912
[TBL] [Abstract][Full Text] [Related]
7. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.
Merrill JT; Wallace DJ; Petri M; Kirou KA; Yao Y; White WI; Robbie G; Levin R; Berney SM; Chindalore V; Olsen N; Richman L; Le C; Jallal B; White B;
Ann Rheum Dis; 2011 Nov; 70(11):1905-13. PubMed ID: 21798883
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Potential of Anti-Interferon α Vaccination on SjS-Related Features in the MRL/lpr Autoimmune Mouse Model.
Killian M; Colaone F; Haumont P; Nicco C; Cerles O; Chouzenoux S; Cathébras P; Rochereau N; Chanut B; Thomas M; Laroche N; Forest F; Grouard-Vogel G; Batteux F; Paul S
Front Immunol; 2021; 12():666134. PubMed ID: 34867938
[TBL] [Abstract][Full Text] [Related]
9. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
Kirou KA; Lee C; George S; Louca K; Peterson MG; Crow MK
Arthritis Rheum; 2005 May; 52(5):1491-503. PubMed ID: 15880830
[TBL] [Abstract][Full Text] [Related]
10. IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model.
Zagury D; Le Buanec H; Mathian A; Larcier P; Burnett R; Amoura Z; Emilie D; Peltre G; Bensussan A; Bizzini B; Gallo RC; Koutouzov S
Proc Natl Acad Sci U S A; 2009 Mar; 106(13):5294-9. PubMed ID: 19279210
[TBL] [Abstract][Full Text] [Related]
11. Interferon
Akita K; Yasaka K; Shirai T; Ishii T; Harigae H; Fujii H
Front Immunol; 2020; 11():498703. PubMed ID: 33633721
[TBL] [Abstract][Full Text] [Related]
12. Inactive disease in patients with lupus is linked to autoantibodies to type I interferons that normalize blood IFNα and B cell subsets.
Bradford HF; Haljasmägi L; Menon M; McDonnell TCR; Särekannu K; Vanker M; Peterson P; Wincup C; Abida R; Gonzalez RF; Bondet V; Duffy D; Isenberg DA; Kisand K; Mauri C
Cell Rep Med; 2023 Jan; 4(1):100894. PubMed ID: 36652906
[TBL] [Abstract][Full Text] [Related]
13. PTPN22 Variant R620W Is Associated With Reduced Toll-like Receptor 7-Induced Type I Interferon in Systemic Lupus Erythematosus.
Wang Y; Ewart D; Crabtree JN; Yamamoto A; Baechler EC; Fazeli P; Peterson EJ
Arthritis Rheumatol; 2015 Sep; 67(9):2403-14. PubMed ID: 26018863
[TBL] [Abstract][Full Text] [Related]
14. A fully human monoclonal antibody with novel binding epitope and excellent neutralizing activity to multiple human IFN-α subtypes: A candidate therapy for systemic lupus erythematosus.
Du P; Xu L; Qiu W; Zeng D; Yue J; Wang S; Huang P; Sun Z
MAbs; 2015; 7(5):969-80. PubMed ID: 26048268
[TBL] [Abstract][Full Text] [Related]
15. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.
McBride JM; Jiang J; Abbas AR; Morimoto A; Li J; Maciuca R; Townsend M; Wallace DJ; Kennedy WP; Drappa J
Arthritis Rheum; 2012 Nov; 64(11):3666-76. PubMed ID: 22833362
[TBL] [Abstract][Full Text] [Related]
16. Interferon-alpha mediates suppression of C-reactive protein: explanation for muted C-reactive protein response in lupus flares?
Enocsson H; Sjöwall C; Skogh T; Eloranta ML; Rönnblom L; Wetterö J
Arthritis Rheum; 2009 Dec; 60(12):3755-60. PubMed ID: 19950271
[TBL] [Abstract][Full Text] [Related]
17. Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures.
Chiche L; Jourde-Chiche N; Whalen E; Presnell S; Gersuk V; Dang K; Anguiano E; Quinn C; Burtey S; Berland Y; Kaplanski G; Harle JR; Pascual V; Chaussabel D
Arthritis Rheumatol; 2014 Jun; 66(6):1583-95. PubMed ID: 24644022
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).
Halfon P; Pérusat S; Bourlière M; Bronowicki JP; Trimoulet P; Benhamou Y; Leroy V; Marcellin P; Foucher J; Penaranda G; Chêne G; Couzigou P;
J Med Virol; 2010 Dec; 82(12):2027-31. PubMed ID: 20981789
[TBL] [Abstract][Full Text] [Related]
19. IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus.
Rose T; Grützkau A; Hirseland H; Huscher D; Dähnrich C; Dzionek A; Ozimkowski T; Schlumberger W; Enghard P; Radbruch A; Riemekasten G; Burmester GR; Hiepe F; Biesen R
Ann Rheum Dis; 2013 Oct; 72(10):1639-45. PubMed ID: 23117242
[TBL] [Abstract][Full Text] [Related]
20. Interferon-α induces altered transitional B cell signaling and function in Systemic Lupus Erythematosus.
Chang NH; Li TT; Kim JJ; Landolt-Marticorena C; Fortin PR; Gladman DD; Urowitz MB; Wither JE
J Autoimmun; 2015 Apr; 58():100-10. PubMed ID: 25678471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
